Clinical ProgressThe company will be presenting full data from Group 1 of the REGEN-007 study, which involves patients who have received rilparencel injections.
Financial StabilityThe company's cash and equivalents at the end of 1Q amounted to $328.5 million, expected to fund operations into mid-2027.
Regulatory PathwayThe planned rilparencel development timeline has been shortened somewhat following FDA's confirmation that a single Ph3 study could support a BLA submission and full approval.